Black women with early stage breast cancer less likely to receive full course of chemotherapy

Black women with stage I or II breast cancer are more likely than their counterparts of other races to abandon chemotherapy before completing their full course of treatment, according to a recent Columbia University Medical Center study.

Published in the Journal of Clinical Oncology (Sept. 20, 2005), the findings shed new light on why breast black cancer patients experience lower survival rates than other women, despite a lower incidence.

"This study is the first to correlate early termination of chemotherapy with racial disparities in breast cancer outcomes," said Dawn Hershman, M.D., M.S., assistant professor of medicine and epidemiology at Columbia University College of Physicians & Surgeons and the Mailman School of Public Health, and the study's lead investigator.

Dr. Hershman and her research team set out to study the association between race and survival with duration of treatment and number of completed chemotherapy cycles. They analyzed the data of 472 stage I and II breast cancer patients enrolled in the tumor registry of the Henry Ford Health System, a large Detroit-area healthcare provider, between 1996 and 2001.

The investigators determined that women who discontinued treatment were more likely to be black and more likely to die than those who completed full chemotherapy cycles. Key findings include:

  • Only 68 percent of black patients (136 out of 202 total) -- compared to 76 percent of white patients (206 out of 270 total) -- completed all prescribed cycles of chemotherapy.
  • 93 percent of all white patients in the study group were alive five years after diagnosis; compared to 81 percent of black patients.
  • A significant number of patients -- 130 out of 472 subjects, nearly 28 percent of the total study population -- did not receive complete treatment (defined here as less than 85 percent of the number of expected cycles).
  • The overall five-year survival rate for the total pat

Contact: Elizabeth Streich
Columbia University Medical Center

Page: 1 2

Related biology news :

1. Wiley to acquire Blackwell Publishing (Holdings) Ltd.
2. Elizabeth Blackburn and Janet Rowley awarded
3. Acute sleep deprivation leads to changes in nighttime urine production for men and women
4. Research aims to identify markers for menopausal women at risk for deadly blood clot
5. The female advantage in kidney disease does not extend to diabetic women
6. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
7. New model for autism suggests women carry the disorder and explains age as a risk factor
8. Awards celebrating women and biotech brilliance
9. High blood pressure medication strategy proves effective in Hispanic women
10. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
11. New research shows vaginal bacteria vary among healthy women, need customized treatment

Post Your Comments:

(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
Cached News: